CRMD vs PFE

CorMedix Inc. exhibits significantly de-risked commercialization with exceptional Q1 2026 results, reporting $127.4 million in revenue and $38.6 million in net income, handily beating revenue estimates. The company substantially raised its FY2026 guidance to $325M-$345M revenue and $115M-$135M adjusted EBITDA, demonstrating strong market adoption of DefenCath and effective integration of the Melin...

Pfizer Inc. remains a mature, large-cap pharmaceutical company with limited potential for the requested 10x growth within 3-5 years, which would require a market cap exceeding $1.4 trillion. While Q1 2026 results showed revenue of $14.45B and adjusted EPS of $0.75, both beating estimates, YoY revenue growth was modest at +5.4% and adjusted EPS declined -18%. Strategic legal wins for VYNDAQEL and C...